Phenoconversion and therapeutic drug monitoring

British Journal of Clinical Pharmacology

Volumn 80, Issue 4, 2015, Pages 777-778

  De Leon, Jose ^a,b,c  

^a Eastern State Hospital   (United States)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

clobazam; clozapine; genotype phenotype mismatch; personalized medicine; pharmacogenetics; risperidone; therapeutic drug monitoring; venlafaxine

Indexed keywords

CLOBAZAM; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C19 INHIBITOR; CYTOCHROME P450 2D6; CYTOCHROME P450 2D6 INHIBITOR; DESVENLAFAXINE; NORCLOBAZAM; PALIPERIDONE; PAROXETINE; RISPERIDONE; VENLAFAXINE; DRUG;

COMPETITIVE INHIBITION; CONCENTRATION PROCESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; GENOTYPE; HEREDITY; HUMAN; LETTER; MEDICAL INFORMATION; NULL ALLELE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOCONVERSION; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); METABOLISM; PROCEDURES;

HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PRECISION MEDICINE;

EID: 84942549635     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12659     Document Type: Letter

References (10)

1. Shah, RR, Smith, RL,. Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clin Pharmacol 2015; 79; 222-40.
2. de Leon, J., The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res 2009; 59: 81-9.
3. Crettol, S, de Leon, J, Hiemke, C, Eap, CB,. Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine. Clin Pharmacol Ther 2014; 95: 254-7.
4. Preskorn, SH, Kane, CP, Lobello, K, Nichols, AI, Fayyad, R, Buckley, G, Focht, K, Guico-Pabia, CJ,. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine. J Clin Psychiatry 2013; 74: 614-21.
5. Ereshefsky, L,. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57 (Suppl. 11): 12-25.
6. Bork, JA, Rogers, T, Wedlund, PJ, de Leon, J,. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999; 60: 469-76.
7. de Leon, J, Sandson, NB, Cozza, KL,. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part II. Psychosomatics 2008; 49: 347-61.
8. de Leon, J, Susce, MT, Pan, RM, Wedlund, PJ, Orrego, ML, Diaz, FJ,. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 2007; 40: 93-102.
9. de Leon, J, Spina, E, Diaz, FJ,. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monit 2013; 35: 30-47.
10. Spina, E, de Leon, J,. Clinical applications of CYP genotyping in psychiatry. J Neural Transm 2015; 122: 5-28.